Furcation DefectsNCT07042204
Effectiveness of E-prf Alone and in Combination With Bioactive Glass Nanoparticles in Grade II Furcation Defects
A study testing Group I (extended platelet-rich fibrin), Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin) and Group III (bioactive glass nanoparticles and covered by a collagen membrane) in people with Furcation Defects, run by Merna Nasser Mohamed Mostafa Ibrahim Elnahas at 1 site in Egypt.
Trial summary
The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Furcation Defects
- What is being tested?
- Group I (extended platelet-rich fibrin), Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin) and Group III (bioactive glass nanoparticles and covered by a collagen membrane)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 3 Jan 2024to 3 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Presence of Glickman's grade II furcation defects in molars probing depth (PD) ≥5 mm horizontal PD ≥3 mm.
- The patients are in good systemic health and had not undergone any periodontal surgery in the areas to be treated within the prior 12 months.
Who cannot join
- Smokers and tobacco chewers.
- Patients that take any medications within the past 6 months that could alter their periodontal status.
- pregnant or lactating females.
- Patients with known allergy to materials or drugs that will be used or prescribed in this study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effectiveness of Extended Platelet-Rich Fibrin (ePRF) Alone and in Combination With Bioactive Glass Nanoparticles in the Treatment of Grade II Furcation Defects
The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.
Read the detailed description
A total of 30 grade II furcation defects will be randomly divided into three groups as follows:
Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.
Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).
Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.
- Conditions
- Furcation Defects
- Being tested
- Group I (extended platelet-rich fibrin), Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin), Group III (bioactive glass nanoparticles and covered by a collagen membrane)
- Medical subject headings
- Furcation Defects
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group I (extended platelet-rich fibrin)Procedure or surgery
mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)Procedure or surgery
bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
Group III (bioactive glass nanoparticles and covered by a collagen membrane)Procedure or surgery
bioactive glass nanoparticles and covered by a collagen membrane
| Study group | Role | What they receive |
|---|---|---|
| Group I | Experimental | 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone. Receives: Procedure: Group I (extended platelet-rich fibrin) |
| Group II | Experimental | 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF). Receives: Procedure: Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin) |
| Group III | Active comparator | 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane. Receives: Procedure: Group III (bioactive glass nanoparticles and covered by a collagen membrane) |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary outcome will be the amount of bone fill vertically and horizontally obtained in the treatment of grade II furcation defects calculated from CBCT data in millimeters
Measured: 6 months follow up
Secondary outcomes (4)
the secondary outcomes include improvements (decrease)of probing depth in millimetres
Using UNC-15 periodontal probe to measure the probing depth from the base of the pocket to the free gingival margin. All measurements will be rounded off to the nearest millimetre.
Measured: 3 and 6 months follow up
the secondary outcomes include improvements (decrease)of clinical attachment level loss in millimetres
using a UNC-15 periodontal probe to measure clinical attachment level loss from the cemento-enamel junction (CEJ) to the pocket depth. All measurements will be rounded off to the nearest millimetre
Measured: 3 and 6 months follow up
the secondary outcomes include improvements (decrease) of gingival recession measured in millimetres
Using a UNC-15 periodontal probe to measure gingival recession from cemento-enamel junction (CEJ) to the free gingival margin. All measurements will be rounded off to the nearest millimetre
Measured: 3 and 6 months follow up
the secondary outcomes include improvements (decrease) of gingival bleeding index
It's performed through gentle probing of the orifice of the gingival crevice using a UNC-15 periodontal probe. If bleeding occurs within 10 seconds a positive finding is recorded, and the number of positive sites is recorded and then expressed as a percentage of the number of the sites examined.
Measured: 3 and 6 months follow up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2025
- Study start3 Jan 2024
- Primary completion3 Jun 2025
- Study completion3 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Furcation DefectsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Merna Nasser Mohamed Mostafa Ibrahim Elnahas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Merna Nasser Mohamed Mostafa Ibrahim Elnahas, Mansoura University
- Investigators
- Merna N Elnahas, Master's degree, Principal investigator, Mansoura Unniversity
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07042204
- Sponsor's protocol ID
- A03011023OM
- Status last verified
- Jan 2026
- First submitted
- 18 Jun 2025
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Extended Platelet-Rich Fibrin (ePRF) Alone and in Combination With Bioactive Glass Nanoparticles in the Treatment of Grade II Furcation Defects
- ClinicalTrials.gov ID
- NCT07042204
- Acronym / sponsor ID
- A03011023OM
- Conditions
- Furcation Defects
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Merna Nasser Mohamed Mostafa Ibrahim ElnahasUniversity, hospital or other
- Study start
- 3 Jan 2024 (actual)
- Primary completion
- 3 Jun 2025 (actual)
- Study completion
- 3 Aug 2025 (actual)
- First posted
- 27 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.
Detailed description
A total of 30 grade II furcation defects will be randomly divided into three groups as follows:
Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.
Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).
Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group I | Experimental | Procedure: Group I (extended platelet-rich fibrin)10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone. |
| Group II | Experimental | Procedure: Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF). |
| Group III | Active comparator | Procedure: Group III (bioactive glass nanoparticles and covered by a collagen membrane)10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Presence of Glickman's grade II furcation defects in molars probing depth (PD) ≥5 mm horizontal PD ≥3 mm.
- The patients are in good systemic health and had not undergone any periodontal surgery in the areas to be treated within the prior 12 months.
Key exclusion criteria (4 listed)
- Smokers and tobacco chewers.
- Patients that take any medications within the past 6 months that could alter their periodontal status.
- pregnant or lactating females.
- Patients with known allergy to materials or drugs that will be used or prescribed in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group I (extended platelet-rich fibrin)mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group | Procedure or surgery | Group I |
| Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF) | Procedure or surgery | Group II |
| Group III (bioactive glass nanoparticles and covered by a collagen membrane)bioactive glass nanoparticles and covered by a collagen membrane | Procedure or surgery | Group III |
Primary outcome
The primary outcome will be the amount of bone fill vertically and horizontally obtained in the treatment of grade II furcation defects calculated from CBCT data in millimeters
Time frame: 6 months follow up
4 secondary outcomes
the secondary outcomes include improvements (decrease)of probing depth in millimetres
Time frame: 3 and 6 months follow up
the secondary outcomes include improvements (decrease)of clinical attachment level loss in millimetres
Time frame: 3 and 6 months follow up
the secondary outcomes include improvements (decrease) of gingival recession measured in millimetres
Time frame: 3 and 6 months follow up
the secondary outcomes include improvements (decrease) of gingival bleeding index
Time frame: 3 and 6 months follow up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Furcation Defects
RecruitingPhase 3
Treatment of Class II Mandibular Furcation Defects
Class II Furcation Defect
Recruiting
Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects
Injectable Platelet-Rich Fibrin, Minimally Invasive
Recruiting
Enamel Matrix Derivative and Xenograft for Mandibular Molar Furcation Defects
Class II Furcation Defect
Recruiting
Morphological Characteristics of Mandibular Molar Furcation Involvement and Efficacy of Regenerative Surgical Treatment
Periodontitis, Periodontitis (Stage 3)
Recruiting
Efficacy of PRF and Xenograft in Treating Mandibular Molar Furcation Involvements
Periodontitis, Furcation Defects
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Merna N Elnahas, Master's degree principal investigator
Mansoura Unniversity
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group I (extended platelet-rich fibrin), Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin) and Group III (bioactive glass nanoparticles and covered by a collagen membrane) in people with Furcation Defects, run by Merna Nasser Mohamed Mostafa Ibrahim Elnahas at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary outcome will be the amount of bone fill vertically and horizontally obtained in the treatment of grade II furcation defects calculated from CBCT data in millimeters (time frame: 6 months follow up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.